Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cizutamig in IgE Mediated Diseases
NCT07408869Phase 1Withdrawn
- Sponsor
- Candid Therapeutics
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of cizutamig in immunoglobulin E-mediated hypersensitivity, food allergy, cow's milk allergy (CMA) and 5 more (2 arms), sponsored by Candid Therapeutics. Primary endpoint: Reduction in IgE levels. Planned start Apr 2026; status: withdrawn.
02
Drugs
cizutamig
03
Conditions
immunoglobulin E-mediated hypersensitivityfood allergycow's milk allergy (CMA)chronic rhinosinusitis (CRS)allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT07408869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07408869.